Search

everythinglearnresearchcommunity

for

Search:↓

All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.